Teva launches generic Actiq
BY DSN STAFF
NORTH WALES, Pa. — Teva Pharmaceuticals on Wednesday announced the launch of its new generic of Actiq (fentanyl citrate) oral transmucosal lozenges.
The lozenges are indicated to manage breakthrough pain in cancer patients 16 years old and older who are currently receiving and tolerating around-the-clock opioid medicine. They are contraindicated in patients who are not tolerant of opioids, management of acute or postoperative pain and patients sensitive to any of the drug’s ingredients.
Teva’s lozenges will be available in 200-, 400-, 600-, 800-, 1200-, and 1600-mcg dosage strengths.
Rx delivery start-up PopRx expands coverage after investment
TORONTO — Canadian prescription delivery start-up PopRx recently secured funding from entrepreneurs featured on Candian Broadcasting Company’s “Next Gen Den” and is growing its scale ahead of a new version of the app, set to launch in 2016. The deal for the funding, which came from OMX president Nicole Verkindt and Shopify CPO Harley Finkelstein, closed today after being pitched on Oct. 6.
The app works by allowing users to take a photo of either their prescription bottle or a paper prescription and letting them order refills for same-day delivery. The app’s developers are working on adding such functionality as real-time delivery updates, patient profiles, automated refills, pill reminders and compliance measures, as well as live chats with local pharmacists.
“The profile and deal with Harley and Nicole has already translated in the expansion of our market, we just announced last week that we can now service the Greater Toronto Area,” PopRx co-founder Dr. Ali Esmail said. We expect that pace to continue with total national coverage in early 2016.”
PopRx joins the ranks of such start-ups as Zipdrug —which services Manhattan (and was featured in our November issue) — and Deliv, which was selected by Walgreens as its partner for the chain’s prescription delivery pilot in the Dallas area.
Loading Post Please Wait...